摘要
Ovariancancerisoneofthemostlethalmalignantgynecologicaltumors.Morethan70%ofpatientswithovariancancerarediagnosedatadvancedstage.The5-yearsurvivalinpatientswithadvancedovariancancerislessthan30%becauseofthelackofeffectivebiomarkersfordiagnosis,prognosis,andpersonalizedtreatment.MicroRNA(miR)isaclassofsmallnoncodingRNAsthatnegativelyregulategeneexpressionprimarilythroughpost-transcriptionalrepression.ManystudiesontissuemiRinovariancancerhavebeencarriedoutandshowgreatpotentialinclinicalpractice.However,tissuesamplesarenoteasilyavailablebecausesamplingcausesinjury.Researchershavestartedtofocusonplasma/serummiR,assumingthatbloodsamplesmayreplacetissuesamplesinmiRresearchinthefuture.Plasma/serummiRresearchisstillinitsearlystages.Studiesonitsfunctionintheearlydiagnosisofovariancancerhaveachievedsomeprogress,butplasma/serummiRprofilingforprognosisandpersonalizedtreatmentofovariancancerremainsunknown.Athoroughunderstandingofthefunctionofplasma/serummiRinovariancancerwillfacilitateearlydiagnosisandimprovetreatmentforovariancancer.
出版日期
2013年03月13日（中国期刊网平台首次上网日期，不代表论文的发表时间）
